Indivior Pharmaceuticals, Inc.
INDV
Jodie situation report
Indivior Pharmaceuticals, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 14 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind INDV
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
RYANRyan Specialty Holdings, Inc.partnerFeb 26, 2026 ▾
“Shareholder Claims A class action lawsuit was filed against Indivior PLC, Mark Crossley (the former CEO of the Company), and Ryan Preblick (the CFO of the Company) on August 2, 2024, alleging violations of certain U.S.”
Depended on by
AQSTAquestive Therapeutics, Inc.customerMay 13, 2026 ▾
“Suboxone was launched by our licensee, Indivior, in 2010.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
INDV is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.